Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4322131 | 0.78 | NOTUM (0.34) | ADORA2AADORA1 | |
| SCHEMBL65897 | 0.72 | — | — | |
| SCHEMBL4512381 | 0.72 | — | — | |
| SCHEMBL7209768 | 0.68 | IKBKB (0.41) | GAAKMT2APDPK1GDAADORA2A | |
| SCHEMBL27720229 | 0.65 | CYP1A2 (0.37) | GAA | |
| SCHEMBL27533747 | 0.64 | — | — | |
| SCHEMBL24025404 | 0.63 | LMNA (0.35) | ERCC1FEN1ERCC4KMT2APDPK1 | |
| Favipiravir SCHEMBL6378032 | 0.63 | ERCC1 (0.32) | ERCC1FEN1ERCC4KMT2APDPK1 | |
| SCHEMBL27865344 | 0.63 | ERCC1 (0.34) | ERCC1FEN1ERCC4PDPK1 | |
| SCHEMBL3378144 | 0.63 | LCK (0.36) | KMT2APDPK1THRBRAB9AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230073216-A1 | Pharmaceutical Compositions of Raltegravir | LUPIN LIMITED (IN) | 2023-03-09 | — | — | US | disclosed |
| US-20210290548-A1 | FORMULATIONS OF RALTEGRAVIR | MERCK SHARP & DOHME CORP. (US) | 2021-09-23 | — | — | US | disclosed |
| WO-2021148992-A1 | PHARMACEUTICAL COMPOSITIONS OF RALTEGRAVIR | LUPIN LIMITED (IN) | 2021-07-29 | — | — | WO | disclosed |
| EP-3801532-A1 | FORMULATIONS OF RALTEGRAVIR | Merck Sharp & Dohme Corp. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-2586444-B1 | Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition | MERCK SHARP & DOHME (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190167591-A1 | Taste-Masked Formulations of Raltegravir | MERCK SHARP & DOHME CORP. (US) | 2019-06-06 | — | — | US | disclosed |
| US-20170312222-A1 | Taste-Masked Formulations of Raltegravir | MERCK SHARP & DOHME CORP. (US) | 2017-11-02 | — | — | US | disclosed |
| EP-1904067-B2 | PHARMACEUTICAL FORMULATION OF CARBOXAMIDE HIV INTEGRASE INHIBITORS CONTAINING A RELEASE RATE CONTROLLING COMPOSITION | MERCK SHARP & DOHME (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-2231621-B1 | PROCESS FOR PREPARING N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8852632-B2 | Pharmaceutical formulation containing a release rate controlling composition | MERCK SHARP & DOHME CORP. (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2006060711-A2 | PHARMACEUTICAL FORMULATION OF CARBOXAMIDE HIV INTEGRASE INHIBITORS CONTAINING A RELEASE RATE CONTROLLING COMPOSITION | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060225-A2 | PROCESS FOR ASYMMETRIC SYNTHESIS OF HEXAHYDROPYRIMIDO[1,2-A] AZEPINE-2-CARBOXAMIDES AND RELATED COMPOUNDS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| EP-1441735-B1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2006-02-22 | — | — | EP | disclosed |
| US-20050282839-A1 | Pyrimidyl phosphonate antiviral compounds and methods of use | GILEAD SCIENCES, INC. | 2005-12-22 | — | — | US | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005070901-A2 | PYRIMIDYL PHOSPHONATE ANTIVIRAL COMPOUNDS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | MSD ITALIA S.R.L. (IT) | 2005-02-03 | — | — | US | disclosed |
| EP-1441735-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003035077-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290548-A1 | FORMULATIONS OF RALTEGRAVIR | KLK5, SUGT1, SLC6A5 | GAA 3356/4885ERCC1 2634/4885FEN1 3040/4885 |
| US-20230073216-A1 | Pharmaceutical Compositions of Raltegravir | CYP3A5, SAMHD1, CYP3A7 | GAA 125/4885ERCC1 1887/4885FEN1 542/4885 |
| US-20050282839-A1 | Pyrimidyl phosphonate antiviral compounds and methods of use | TYMP, MTAP, PNP | GAA 767/4885ERCC1 1162/4885FEN1 86/4885 |
| US-20170312222-A1 | Taste-Masked Formulations of Raltegravir | TAS2R41, TAS2R39, TAS2R40 | GAA 43/4885ERCC1 2548/4885FEN1 4117/4885 |
| US-20190167591-A1 | Taste-Masked Formulations of Raltegravir | TAS2R41, TAS2R39, TAS2R40 | GAA 43/4885ERCC1 2548/4885FEN1 4117/4885 |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | TYMP, PNP, PIKFYVE | GAA 900/4885ERCC1 879/4885FEN1 60/4885 |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | IMPDH1, CCNI, REV1 | GAA 2196/4885ERCC1 1448/4885FEN1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.